STAT+: Real-world psilocybin data suggest need for close monitoring

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a fair number of data readouts for a summer Tuesday, so let’s get right into it.

Amylyx reports success in a pivotal trial

Amylyx this morning said that, in a pivotal trial, its experimental drug significantly helped patients who experience sudden drops in blood sugar after bariatric surgery.

Continue to STAT+ to read the full story…